

Global Markets for Orphan Drugs

<https://marketpublishers.com/r/G3527CFD3F4AEN.html>

Date: January 2024

Pages: 189

Price: US\$ 5,500.00 (Single User License)

ID: G3527CFD3F4AEN

Abstracts

Report Scope:

The scope of this study includes orphan drugs used in the global pharmaceutical markets. This report analyzes the therapeutic applications of orphan drugs in rare and orphan diseases as well as examines the regulatory framework, patents, and recent innovations in the industry. The report also analyzes each submarket and its applications, projections, and market shares. Technological issues include the latest trends and developments.

This report covers the regional segmentation included as North America, Europe, Asia-Pacific, and Rest of the World. This report also analyzes the regulatory framework for the clinical trials of orphan drugs in rare and orphan diseases. The report examines the trends and characteristics of clinical trials conducted on rare diseases from 1999-2018, using information from various sources. In addition, this report provides an overview of the global orphan drugs market and its competitive landscape. This report also examines acquisition strategies and collaborations, discusses the market's strengths and weaknesses considering new technologies, and analyzes the industry's growing competition and changing customer needs.

Report Includes:

33 data tables and 46 additional tables

Overview and an up-to-date analysis of the global markets for orphan drugs (ODs) for rare diseases treatment

Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and

projections of compound annual growth rates (CAGRs) through 2028

Highlights of the current and future market potential of orphan drugs, along with a detailed analysis of the market drivers, restraints, and opportunities

Estimate of the actual market size and revenue forecast for the global orphan drugs market, and its corresponding market share analysis based on the product type, therapeutic area, and region

Analysis of market growth opportunities with a holistic review of Porter's five forces model and PESTLE analyses considering the micro%li%and macroeconomic factors prevailing in the marketplace

Discussion of sustainability trends and factors in the orphan drugs market, with emphasis on consumer attitudes, ESG score analysis, future of ESG, case study, and the ESG practices followed

Analyses of the novel therapeutic applications of orphan drugs in rare and orphan diseases as well as examination of the regulatory framework, patents, and recent innovations in the industry

Review of the current status and trends in clinical trials for the development of drugs in rare diseases among the three registries from the U.S., EU and Japan

Discussion of successful orphan medicinal products, rising influence of pharmacogenomics in the ODs market, information on specific rare diseases for which orphan drugs exist

Assessment of the most promising therapeutic areas in the industry and leading orphan drugs in these areas

Overview of the industry structure for orphan drugs, pricing and reimbursement policies, COVID-19 impact, and market share analysis of the leading manufacturers of orphan drugs along with their SWOT analyses

Company profiles of major players within the industry, including AstraZeneca Plc, Eisai Co. Ltd., Bristol Myers Squibb and Pfizer Inc.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in this Update?
Methodology
Information Sources
Geographic Breakdown
Segmentation Breakdown

CHAPTER 2 SUMMARY AND HIGHLIGHTS

Market Outlook
Market Summary

CHAPTER 3 MARKET OVERVIEW

Market and Technology Background
Global Definitions of Rare Diseases by Country/Region
U.S.
EU
Taiwan
Japan
Australia
Singapore
South Korea
Switzerland
Brazil

CHAPTER 4 MARKET DYNAMICS

Overview
Drivers
Favorable Orphan Drug Act and Similar Legislation
Technological Advances in Genomics
Lack of Competition from Generic Drugs

Patent Extensions
Premium Pricing of Orphan Drugs
Innovations in Manufacturing Technologies
Increasing Collaborations and Licensing Agreements
Restraints
Lack of Trained Professionals
Vulnerable Target Groups
Regulatory Challenges
Opportunities
Huge Product Pipeline of New Orphan Drugs
Regulatory Landscape
U.S.
Europe
Japan
Taiwan
South Korea

CHAPTER 5 GLOBAL MARKET FOR ORPHAN DRUGS BY PRODUCT TYPE

Biological Orphan Drugs
Non-biological Orphan Drugs

CHAPTER 6 GLOBAL MARKET FOR ORPHAN DRUGS BY THERAPEUTIC APPLICATION

Oncology
Blood Disorders
Central Nervous System
Respiratory System
Immunomodulators
Cardiovascular Therapies
Endocrine System
Musculoskeletal System
Others

CHAPTER 7 GLOBAL MARKET FOR ORPHAN DRUGS BY REGION

Global Market Share Analysis
North America

Europe

Asia-Pacific

Rest of the World (RoW)

CHAPTER 8 ESG OUTLOOK IN THE ORPHAN DRUGS MARKET

Introduction to ESG

Importance of ESG in the Orphan Drug Industry

ESG Pillars in the Orphan Drugs Industry

ESG Ratings and Metrics: Understanding the Data

ESG practices in the Orphan Drug Industry

Concluding Remarks from BCC Research

CHAPTER 9 ORPHAN DRUGS EXCLUSIVITY AND PRICING POLICIES

Reimbursed Price of ODs: Current Strategies and Potential Improvements

Comprehensive Value Assessment

Early Dialogues

Innovative Reimbursement Approaches

Societal Participation in Producing ODs

CHAPTER 10 CLINICAL TRIALS ON DRUGS FOR RARE DISEASES

List of Clinical Trials on Drugs for Rare Diseases

CHAPTER 11 COMPETITIVE LANDSCAPE

Top 10 Selling Orphan Drugs Globally

Market Share Analysis

CHAPTER 12 COMPANY PROFILES

ABBVIE INC.

ASTELLAS PHARMA INC.

ASTRAZENECA PLC

BRISTOL MYERS SQUIBB

EISAI CO. LTD.

ELI LILLY AND CO.

F. HOFFMANN-LA ROCHE LTD.

MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
SANOFI S.A.
TAKEDA PHARMACEUTICAL CO. LTD.

CHAPTER 13 APPENDIX: ACRONYMS

Acronyms

List Of Tables

LIST OF TABLES

Summary Table : Global Market for Orphan Drugs, by Product Type, Through 2028

Table 1 : Prevalence of Rare Diseases

Table 2 : Market Dynamics: Impact Analysis

Table 3 : Orphan-Designation Application Documents

Table 4 : Summary of Orphan Designation in Europe

Table 5 : Overview of Organizations and Responsibilities in Japan

Table 6 : Comparison of the Regulation of Rare Diseases and Orphan Drugs Worldwide

Table 7 : Global Market for Orphan Drugs, by Product Type, Through 2028

Table 8 : Global Market for Biological Orphan Drugs, by Region, Through 2028

Table 9 : Global Market for Non-biological Orphan Drugs, by Region, Through 2028

Table 10 : Global Market for Oncology Orphan Drugs, by Region, Through 2028

Table 11 : Global Market for Blood Disorders Orphan Drugs, by Region, Through 2028

Table 12 : Global Market for Central Nervous System Orphan Drugs, by Region, Through 2028

Table 13 : Global Market for Respiratory System Orphan Drugs, by Region, Through 2028

Table 14 : Global Market for Immunomodulator Therapies Orphan Drugs, by Region, Through 2028

Table 15 : Global Market for Cardiovascular Therapies Orphan Drugs, by Region, Through 2028

Table 16 : Global Market for Endocrine System Orphan Drugs, by Region, Through 2028

Table 17 : Global Market for Musculoskeletal System Orphan Drugs, by Region, Through 2028

Table 18 : Global Market for Other Therapeutic Applications Orphan Drugs, by Region, Through 2028

Table 19 : Global Market Shares of Orphan Drugs, by Region, 2023

Table 20 : North American Market for Orphan Drugs, by Product Type, Through 2028

Table 21 : North American Market for Orphan Drugs, by Therapeutic Application, Through 2028

Table 22 : European Market for Orphan Drugs, by Product Type, Through 2028

Table 23 : European Market for Orphan Drugs, by Therapeutic Application, Through 2028

Table 24 : Asia-Pacific Market for Orphan Drugs, by Product Type, Through 2028

Table 25 : Asia-Pacific Market for Orphan Drugs, by Therapeutic Application, Through 2028

2028

Table 26 : Rest of the World Market for Orphan Drugs, by Product Type, Through 2028

Table 27 : Rest of the World Market for Orphan Drugs, by Therapeutic Application, Through 2028

Table 28 : ESG Ratings and Metrics

Table 29 : Environmental Performance in the Orphan Drug Market

Table 30 : Social Performance in the Orphan Drugs Market

Table 31 : Governance Performance in the Orphan Drugs Market

Table 32 : ESG Rankings for Major Orphan Drugs Companies, 2023*

Table 33 : Clinical Trials in Drugs for Rare Diseases

Table 34 : Global Market Ranking of the Top 10 Selling Orphan Drugs, 2022

Table 35 : Global by Company Market Shares of Orphan Drugs, 2022

Table 36 : AbbVie Inc.: Company Snapshot

Table 37 : AbbVie Inc.: Financial Performance, 2022

Table 38 : AbbVie Inc.: News, 2020-2022

Table 39 : AbbVie Inc.: Products

Table 40 : Astellas Pharma Inc.: Company Snapshot

Table 41 : Astellas Pharma Inc.: Financial Performance, 2023

Table 42 : Astellas Pharma Inc.: News, 2023

Table 43 : Astellas Pharma Inc.: Products

Table 44 : AstraZeneca Plc.: Company Snapshot

Table 45 : AstraZeneca Plc: Financial Performance, 2022

Table 46 : AstraZeneca Plc: News, 2022 and 2023

Table 47 : AstraZeneca Plc: Products

Table 48 : Bristol Myers Squibb: Company Snapshot

Table 49 : Bristol Myers Squibb: Financial Performance, 2022

Table 50 : Bristol Myers Squibb: News, 2021-2023

Table 51 : Bristol Myers Squibb: Products

Table 52 : Eisai Co. Ltd.: Company Snapshot

Table 53 : Eisai Co. Ltd.: Financial Performance, 2022

Table 54 : Eisai Co. Ltd.: News, 2021 and 2022

Table 55 : Eisai Co. Ltd.: Products

Table 56 : Eli Lilly and Co.: Company Snapshot

Table 57 : Eli Lilly and Co.: Financial Performance, 2022

Table 58 : Eli Lilly and Co.: Products

Table 59 : F. Hoffmann-La Roche Ltd.: Company Snapshot

Table 60 : F. Hoffmann-La Roche Ltd.: Financial Performance, 2022

Table 61 : F. Hoffmann-La Roche Ltd.: Products

Table 62 : Merck & Co. Inc.: Company Snapshot

Table 63 : Merck & Co. Inc.: Financial Performance, 2022

Table 64 : Merck & Co. Inc.: Products

Table 65 : Novartis AG: Company Snapshot

Table 66 : Novartis AG: Financial Performance, 2022

Table 67 : Novartis AG: News, 2020-2022

Table 68 : Novartis AG: Products

Table 69 : Pfizer Inc.: Company Snapshot

Table 70 : Pfizer Inc.: Financial Performance, 2022

Table 71 : Sanofi S.A.: Company Snapshot

Table 72 : Sanofi S.A.: Financial Performance, 2022

Table 73 : Sanofi S.A.: Products

Table 74 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot

Table 75 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, 2022

Table 76 : Takeda Pharmaceutical Co. Ltd.: News, 2023

Table 77 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio

Table 78 : Acronyms Used in This Report

List Of Figures

LIST OF FIGURES

Summary Figure : Global Market for Orphan Drugs, by Product Type, 2020-2028

Figure 1 : Orphan Drugs Market Dynamics

Figure 2 : Orphan Designation Process, Japan

Figure 3 : Orphan Designation Consultation and Evaluation, Japan

Figure 4 : Global Market for Orphan Drugs, by Product Type, 2020-2028

Figure 5 : Global Market for Biological Orphan Drugs, by Region, 2020-2028

Figure 6 : Global Market for Non-biological Orphan Drugs, by Region, 2020-2028

Figure 7 : Global Market Shares of Orphan Drugs, by Therapeutic Application, 2023

Figure 8 : Global Market for Oncology Orphan Drugs, by Region, 2020-2028

Figure 9 : Global Market for Blood Disorders Orphan Drugs, by Region, 2020-2028

Figure 10 : Global Market for Central Nervous System Orphan Drugs, by Region, 2020-2028

Figure 11 : Global Market for Respiratory System Orphan Drugs, by Region, 2020-2028

Figure 12 : Global Market for Immunomodulator Therapies Orphan Drugs, by Region, 2020-2028

Figure 13 : Global Market for Cardiovascular Therapies Orphan Drugs, by Region, 2020-2028

Figure 14 : Global Market for Endocrine System Orphan Drugs, by Region, 2020-2028

Figure 15 : Global Market for Musculoskeletal System Orphan Drugs, by Region, 2020-2028

Figure 16 : Global Market for Other Therapeutic Applications Orphan Drugs, by Region, 2020-2028

Figure 17 : Global Market Shares of Orphan Drugs, by Region, 2023

Figure 18 : North American Market for Orphan Drugs, by Product Type, 2020-2028

Figure 19 : North American Market for Orphan Drugs, by Therapeutic Application, 2020-2028

Figure 20 : European Market for Orphan Drugs, by Product Type, 2020-2028

Figure 21 : European Market for Orphan Drugs, by Therapeutic Application, 2020-2028

Figure 22 : Asia-Pacific Market for Orphan Drugs, by Product Type, 2020-2028

Figure 23 : Asia-Pacific Market for Orphan Drugs, by Therapeutic Application, 2020-2028

Figure 24 : Rest of the World Market for Orphan Drugs, by Product Type, 2020-2028

Figure 25 : Rest of the World Market for Orphan Drugs, by Therapeutic Application, 2020-2028

Figure 26 : Conceptual Framework for Analyzing Current Strategies for Pricing

Definition

Figure 27 : Global Company Market Shares of Orphan Drugs, 2022

Figure 28 : AbbVie Inc.: Financial Performance, 2021 and 2022

Figure 29 : AbbVie Inc.: Revenue Share, by Segment, 2022

Figure 30 : AbbVie Inc.: Revenue Share, by Region, 2022

Figure 31 : Astellas Pharma Inc.: Financial Performance, 2022 and 2023

Figure 32 : Astellas Pharma Inc.: Revenue Share, by Segment, 2023

Figure 33 : Astellas Pharma Inc.: Revenue Share, by Region/Country, 2023

Figure 34 : AstraZeneca Plc: Financial Performance, 2021 and 2022

Figure 35 : AstraZeneca Plc: Revenue Share, by Segment, 2022

Figure 36 : AstraZeneca Plc: Revenue Share, by Region, 2022

Figure 37 : Bristol Myers Squibb: Financial Performance, 2021 and 2022

Figure 38 : Bristol Myers Squibb: Revenue Share, by Region, 2022

Figure 39 : Eisai Co. Ltd.: Financial Performance, 2021 and 2022

Figure 40 : Eisai Co. Ltd.: Revenue Share, by Segment, 2022

Figure 41 : Eli Lilly and Co.: Financial Performance, 2021 and 2022

Figure 42 : Eli Lilly and Co.: Revenue Share, by Segment, 2022

Figure 43 : Eli Lilly and Co.: Revenue Share, by Region, 2022

Figure 44 : F. Hoffmann-La Roche Ltd.: Financial Performance, 2021 and 2022

Figure 45 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Segment, 2022

Figure 46 : Merck & Co. Inc.: Financial Performance, 2021 and 2022

Figure 47 : Merck & Co. Inc.: Revenue Share, by Business Unit, 2022

Figure 48 : Merck & Co. Inc.: Revenue Share, by Region, 2022

Figure 49 : Novartis AG: Financial Performance, 2021 and 2022

Figure 50 : Novartis AG: Revenue Share, by Segment, 2022

Figure 51 : Novartis AG: Revenue Share, by Region, 2022

Figure 52 : Pfizer Inc.: Financial Performance, 2021 and 2022

Figure 53 : Pfizer Inc.: Revenue Share, by Segment, 2022

Figure 54 : Pfizer Inc.: Revenue Share, by Region, 2022

Figure 55 : Sanofi S.A.: Financial Performance, 2021 and 2022

Figure 56 : Sanofi S.A.: Revenue Share, by Segment, 2022

Figure 57 : Sanofi S.A.: Revenue Share, by Region, 2022

Figure 58 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, 2021 and 2022

Figure 59 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, 2022

Figure 60 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region/Country, 2022

I would like to order

Product name: Global Markets for Orphan Drugs

Product link: <https://marketpublishers.com/r/G3527CFD3F4AEN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3527CFD3F4AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970